Precision drug development*
Through our clinical development strategy, we strive to achieve three fundamental principles. We believe that following these principles may lead to more precise, effective, and safer therapies.
- 1. Using companion imaging agents to identify appropriate patients and indications.
- 2. Improving the potency of the therapy by using more highly active drugs and more frequent dosing.
- 3. Decreasing toxicity through precise targeting so the therapy can be combined with other drugs.
Endocyte is currently sponsoring clinical trials related to several oncology product candidates.
VYNFINIT® (VINTAFOLIDE) Cancer: Folate-Receptor-Targeted Chemotherapy
EC1456 Solid Tumors: FOLIC ACID-TUBULYSIN CONJUGATE
EC1169 PSMA Tubulysin
Medical professionals requesting additional information may contact firstname.lastname@example.org
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.